Source: CNBC
“Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum grows for using versions of the drugs as mental health treatments. The transaction gives Lilly access to AtaiBeckley’s experimental DMT-based drug that’s being studied in Phase 3 clinical trials for treatment-resistant depression. AtaiBeckley is developing several other psychedelics for mental health conditions, including one related to MDMA, also known as ecstasy.” (07/16/26)
https://www.cnbc.com/2026/07/16/eli-lilly-to-buy-psychedelics-maker-ataibeckley-2point8-billion.html